BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37403579)

  • 21.
    Şimşek DH; Şanlı Y; Kuyumcu S; Başaran B; Mudun A
    Ann Nucl Med; 2018 May; 32(4):297-301. PubMed ID: 29468487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
    Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 18 F-MFBG and 68 Ga-DOTATATE PET/CT in the Imaging of Metastatic Paraganglioma and Pheochromocytoma.
    Deng M; Shu Q; Hu M; Chen Y; Cai L
    Clin Nucl Med; 2022 Dec; 47(12):e735-e737. PubMed ID: 35777982
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Krokhmal AA; Kwatra N; Drubach L; Weldon CB; Janeway KA; DuBois SG; Kamihara J; Voss SD
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29740. PubMed ID: 35484995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
    Ryder SJ; Love AJ; Duncan EL; Pattison DA
    Clin Endocrinol (Oxf); 2021 Jul; 95(1):13-28. PubMed ID: 33296100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in the management of pheochromocytoma and paraganglioma.
    Tanabe A; Naruse M
    Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of
    Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
    Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.
    Janssen I; Blanchet EM; Adams K; Chen CC; Millo CM; Herscovitch P; Taieb D; Kebebew E; Lehnert H; Fojo AT; Pacak K
    Clin Cancer Res; 2015 Sep; 21(17):3888-95. PubMed ID: 25873086
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
    Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
    Kornaczewski ER; Pointon OP; Burgess JR
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
    Taïeb D; Jha A; Treglia G; Pacak K
    Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
    Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on adult forms of hereditary pheochromocytomas and paragangliomas.
    Dariane C; Goncalves J; Timsit MO; Favier J
    Curr Opin Oncol; 2021 Jan; 33(1):23-32. PubMed ID: 33186184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pheochromocytomas and paragangliomas.
    Yen K; Lodish M
    Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of [
    Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
    Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery.
    Nockel P; El Lakis M; Gaitanidis A; Merkel R; Patel D; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Ann Surg; 2019 Apr; 269(4):741-747. PubMed ID: 29334561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas.
    Jing H; Li F; Wang L; Wang Z; Li W; Huo L; Zhang J
    Clin Nucl Med; 2017 Jul; 42(7):525-529. PubMed ID: 28481789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.